959857-84-2Relevant academic research and scientific papers
COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT
-
Page/Page column 46, (2009/12/24)
Disclosed herein are an HIF-1 inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient. The HIF-1 inhibitor shows anticancer activity thanks to the inhibition activity against HIF-1, a transcription factor which plays an important role in the growth and metastasis of cancer, but not to general cytotoxicity. Thus, the HIF-inhibitor and a pharmaceutically acceptable salt thereof can be used as a therapeutic for various cancers such as liver cancer; stomach cancer and breast cancer. Also, the compound having inhibition activity against HIF-1 is useful in the treatment of diabetic retinopathy and arthritis, which are aggravated by HIF-1-mediated VEGF expression.
COMPOUNDS TEAT INHIBIT HBF-I ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT
-
Page/Page column 67, (2008/06/13)
Disclosed herein are an HIF-I inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient The BDDF-I inhibitor shows anticancer activity thanks to the inhibition activity against HIF-I, a transcription factor which plays an important role in the growth and metastasis of cancer, but not to general cytotoxicity. Thus, the HIF-inhibitor and a pharmaceutically acceptable salt thereof can be used as a therapeutic for various cancers such as liver cancer, stomach cancer and breast cancer. Also, the compound having inhibition activity against HDDF-I is useful in the treatment of diabetic retinopathy and arthritis, which are aggravated by HEF-l-mediated VEGF expression.
Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1α inhibitors
Boovanahalli, Shanthaveerappa K.,Jin, Xuejun,Jin, Yinglan,Kim, Jin Hwan,Dat, Nguyen Tien,Hong, Young-Soo,Lee, Jeong Hyung,Jung, Sang-Hun,Lee, Kyeong,Lee, Jung Joon
, p. 6305 - 6310 (2008/09/17)
We report a new series of HIF-1α inhibitors which were obtained through structural modifications of previously reported lead 1. The in vitro inhibitory potencies of newly synthesized compounds were evaluated against hypoxia-induced HIF-1 activation using
